GlassScriptPhysician profile
Bill Quach
NPI 1912403114
$1,831.84
in general payments reported to CMS, 2019-2025
20 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $480 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791 · Education: $41.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.81 |
| Education | $41.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $394.92 | 2024-2025 | |
| United Therapeutics Corporation | $228.20 | 2024 | Remodulin |
| Janssen Biotech, INC. | $215.88 | 2024-2025 | Tremfya |
| Madrigal Pharmaceuticals | $169.83 | 2025 | Rezdiffra |
| Orphalan INC | $127.43 | 2025 | Cuvrior |
| Organon LLC | $104.93 | 2024-2025 | Hadlima, Renflexis |
| Gilead Sciences, INC. | $103.51 | 2024-2025 | |
| Celltrion USA INC. | $73.78 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $62.39 | 2024-2025 | Iqirvo, Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $61.55 | 2024-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $54.16 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $41.03 | 2024 | Resolution 360 Clip |
| Braintree Laboratories, INC. | $36.44 | 2025 | Suflave |
| Lilly USA, LLC | $35.96 | 2025 | Omvoh |
| Novo Nordisk INC | $32.02 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.84 | 2025 | |
| Enterra Medical, INC. | $20.22 | 2025 | |
| Aimmune Therapeutics, INC. | $19.55 | 2025 | Vowst |
| Capsovision, INC. | $14.90 | 2025 | Capsocam Plus |
| Ardelyx, INC. | $14.30 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Quach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.